Jubilant Life stock rises after Q4FY18 PAT gains
The company’s consolidated revenue in Q4FY18 rose 40.9% to Rs2,252cr vs Rs1,598cr in Q4FY17.
Jubilant Life Sciences Ltd is currently trading at Rs857.05 up by Rs10.3 or 1.22% from its previous closing of Rs846.75 on the BSE. PAT grew by 2.3% yoy to Rs152.4cr. The PAT came lower as company had booked one‐time charges, adjusted for which PAT growth is higher at 63.3% yoy to Rs243cr in Q4FY18.
The company’s consolidated revenue in Q4FY18 rose 40.9% to Rs2,252cr vs 1,598cr in Q4FY17.
EBITDA in Q4FY18 was up 50.1% yoy to Rs458cr vs Rs305cr in Q4FY17.EBITDA margins were at 20.3% in Q4FY18 vs. 20.2% in Q3FY18 and 19.1% in Q4FY17.
The pharmaceutical segment sales grew by 54% yoy to Rs1,238cr, while Life Sciences Ingredient (LSI) segment sales grew by 43% yoy to 968cr in Q4FY18.
The scrip opened at Rs862 and has touched a high and low of Rs880 and Rs851.50 respectively.